GlassScriptPhysician profile
David Dunaway
NPI 1619321619
$56,937.10
in general payments reported to CMS, 2019-2025
29 companies · $45K in 2025
The $45K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.00 · 2020: $99.00 · 2021: $530 · 2022: $2,812 · 2023: $5,437 · 2024: $2,858 · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Food and Beverage: $8,926 · Travel and Lodging: $3,701 · Consulting Fee: $2,268 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,250.00 |
| Food and Beverage | $8,925.52 |
| Travel and Lodging | $3,700.95 |
| Consulting Fee | $2,268.00 |
| Education | $279.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $45,495.36 | 2021-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $3,187.70 | 2022-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $2,011.04 | 2019-2025 | Tremfya, Remicade, Stelara |
| Sun Pharmaceutical Industries INC. | $1,174.40 | 2021-2025 | Winlevi, Ilumya, Absorica Ld |
| Genzyme Corporation | $849.30 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $644.56 | 2021-2025 | |
| Lilly USA, LLC | $635.29 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $510.73 | 2021-2025 | Opzelura |
| Janssen Scientific Affairs, LLC | $392.30 | 2022-2023 | Tremfya |
| Galderma Laboratories, L.P. | $365.98 | 2023-2025 | Nemluvio, Aklief, Epsolay |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $316.33 | 2021-2024 | Jublia, Arazlo, Duobrii |
| E.R. Squibb & Sons, L.L.C. | $242.00 | 2022-2024 | Sotyktu |
| Amgen INC. | $151.98 | 2022-2025 | Otezla |
| Organon LLC | $99.98 | 2025 | Vtama |
| Strata Skin Sciences, INC. | $96.01 | 2024-2025 | Xtrac |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $91.52 | 2022 | |
| Pfizer INC. | $90.24 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $89.15 | 2023-2024 | Zoryve |
| Almirall LLC | $81.95 | 2023-2024 | Klisyri, Seysara |
| Paratek Pharmaceuticals, INC. | $78.84 | 2023-2025 | Nuzyra |
| Helsinn Therapeutics (U.S.), INC. | $74.95 | 2023-2025 | Valchlor |
| Sanofi-Aventis U.S. LLC | $68.99 | 2022 | |
| Dermavant Sciences, INC. | $58.77 | 2023 | Vtama |
| Ucb, INC. | $36.01 | 2025 | Bimzelx |
| Botanix Sb INC | $29.87 | 2025 | Sofdra |
| Genentech USA, INC. | $20.85 | 2025 | Xolair |
| Epi Health, LLC | $16.20 | 2022 | |
| Journey Medical Corporation | $13.55 | 2023 | |
| Mission Pharmacal Company | $13.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dunaway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.